StockData
HeartSciences Inc. logo

HeartSciences Inc. (HSCS) company profile

HSCSNasdaqFinance ServicesFiscal year ends April 30Also trades as HSCSW
Số liệu tài chính tới Q1 năm tài chính 2027, quý kết thúc ngày Jul 31, 2026Last filing: 10-Q on Sep 14, 2026Score 3/30
$2.06−0.02 (-0.96%)

Close on Nov 17, 2026Market cap $9.89MP/E –Yield 0.00%

About HeartSciences

Finance Services, SIC 6199

HeartSciences is a medical technology company that develops artificial intelligence-driven electrocardiography solutions to enhance cardiac care. Its flagship product is MyoVista Insights, a cloud-based, device-agnostic ECG data management platform designed to organize clinical workflows and integrate multi-vendor AI-ECG algorithms. The company also develops the MyoVista wavECG device, a point-of-care resting twelve-lead ECG system engineered to host embedded cardiac analysis algorithms. HeartSciences serves healthcare providers ranging from primary care settings to large hospital systems and cardiology practices seeking modernized ECG infrastructure and risk assessment tools.

The company operates primarily in the United States and maintains international intellectual property protections across jurisdictions including Europe, Canada, Japan, India, and China. HeartSciences employs a five-person research and development staff to advance its proprietary software and device capabilities. The company’s headquarters are not stated in the provided text.

Summary of the business section of HeartSciences's latest annual report, written by StockData.

Company profile

Company

Legal name
HeartSciences Inc.
Founded
2007
Headquarters
Southlake, TX
Address
550 Reserve St, Suite 360 76092
Phone
(682) 237-7781
Industry
Finance Services
Incorporated in
Texas
Fiscal year ends
April 30
Auditor
HASKELL & WHITE LLP, Irvine, California

Stock & identifiers

Ticker
HSCS
Other tickers
HSCSW
Exchange
Nasdaq
IPO date
Jun 17, 2022
Shares outstanding
5M, Sep 11, 2026
Public float
$10.40M, Sep 30, 2023
Filer category
<br>Emerging growth company
Stock splits
1-for-100 reverse, May 17, 2024
SEC CIK
1468492
CUSIP
42254E302
ISIN
US42254E3027
FIGI
BBG0185L0044
Share class FIGI
BBG0185L0106
LEI
254900TRRGAWZYCX1Q54
EIN
26-1344466

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Andrew SimpsonSee Remarks, Director499,382
Danielle WatsonSee Remarks–
Mark T. HilzSee Remarks4,793
David R. WellsDirector–
Bruce BentDirector1,638
Brian SzymczakDirector6,060

Executive compensation, fiscal 2025

Summary compensation table from the latest proxy statement

ExecutiveSalaryBonusOption awardsTotalvs. prior year
Andrew Simpson
President, Chief Executive Officer and Chairman of the Board of Directors
$345.83K$65.00K$116.34K$527.17K+76%
Mark Hilz
Chief Operating Officer and Secretary
$337.88K$65.00K$116.34K$519.22K+73%
Danielle Watson
Chief Financial Officer and Treasurer
$203.67K$30.00K$23.27K$256.94K+43%

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

IPO

From the final prospectus (Form 424B4) and the first day of trading

Offering

Type
Initial public offering
Final prospectus filed
Jun 17, 2022
Offer price
$4.25
Securities offered
1,500,000
Gross proceeds
$6.38M
Exchange
Nasdaq
First trading day
Jun 15, 2022
First-day close
$1.70-60.0%
Lock-up ends (est.)
Dec 12, 2022

“The initial public offering price is $4.25 per Unit.”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

Corporate history

Events identified from SEC filings

See a number that looks wrong?